Free tool
Drug Trial Radar: Cardiovascular and metabolic
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
69
Not yet recruiting, industry sponsors, Cardiovascular and metabolic, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting193
- Completed2,436
69 trials
Showing 1 to 25, recently updated first.
- BHB-1893 vs. Placebo for Symptomatic Non-obstructive Hypertrophic CardiomyopathyPivotal-lookingNot yet recruiting
Braveheart Bio, Inc.Industry
NCT07946107 · 600 participants (planned) · Start Dec 2026 · Primary completion Dec 2029
Drug: BHB-1893 · For: Cardiomyopathy, Hypertrophic Non-Obstructive
- A Study of EloraTZP in Adult Participants With Obesity Without Type 2 DiabetesPivotal-lookingNot yet recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07881432 · 2,115 participants (planned) · Start Dec 2026 · Primary completion Oct 2029
Drug: eloralintide and tirzepatide; Eloralintide and 2 more · For: Obesity
Sites: Mesa, Arizona; Scottsdale, Arizona; Tucson, Arizona · 161 sites in all
- Intravenous Recombinant Human Prourokinase (rhPro-UK) for Acute Ischemic Stroke Within 4.5 to 24 Hours of OnsetPivotal-lookingNot yet recruiting
Tasly Biopharmaceuticals Co., Ltd.Industry
NCT07942584 · 978 participants (planned) · Start Nov 30, 2026 · Primary completion Mar 1, 2029
Drug: Recombinant Human Prourokinase for Injection (rhPro-UK); Aspirin Enteric-Coated Tablets and 2 more · For: Acute Ischemic Stroke AIS
Sites: Beijing, China
- A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular RiskPivotal-lookingNot yet recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07900633 · 3,000 participants (planned) · Start Dec 2026 · Primary completion Nov 2029
Drug: Eloralintide; Placebo · For: Obesity; Overweight; Cardiovascular Diseases and 1 more
Sites: Birmingham, Alabama; Huntsville, Alabama; Apache Junction, Arizona · 308 sites in all
- A Study to Evaluate the Safety and Efficacy of Mavacamten in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (SOLSTICE-HCM)Pivotal-lookingNot yet recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07940777 · 500 participants (planned) · Start Dec 29, 2026 · Primary completion Jul 21, 2029
Drug: Mavacamten · For: Non-obstructive Hypertrophic Cardiomyopathy
- A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)Pivotal-lookingNot yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07839585 · 352 participants (planned) · Start Nov 26, 2026 · Primary completion Jan 8, 2030
Drug: Sotatercept; Placebo · For: Pulmonary Hypertension
- AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or BothPivotal-lookingNot yet recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07931573 · 1,200 participants (planned) · Start Nov 10, 2026 · Primary completion Jul 4, 2028
Drug: Zenagamtide; Semaglutide and 1 more · For: Type 2 Diabetes
Sites: Phoenix, Arizona; La Jolla, California; La Mesa, California · 230 sites in all
- A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExercisePivotal-lookingNot yet recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07931495 · 200 participants (planned) · Start Nov 10, 2026 · Primary completion Jun 5, 2028
Drug: Zenagamtide; Placebo · For: Diabetes Mellitus, Type 2
Sites: Fountain Valley, California; Los Angeles, California; Spring Valley, California · 48 sites in all
- A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve PatientsPivotal-lookingNot yet recruiting
AstraZenecaAstraZeneca (AZN)
NCT07930507 · 204 participants (planned) · Start Dec 21, 2026 · Primary completion Oct 11, 2027
Drug: Laroprovstat; Rosuvastatin 1 and 5 more · For: Hypercholesterolemia
Sites: Beijing, China; Chifeng, China; Guangzhou, China · 42 sites in all
- A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or BothPivotal-lookingNot yet recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07931547 · 450 participants (planned) · Start Nov 10, 2026 · Primary completion Jul 31, 2028
Drug: Zenagamtide · For: Type 2 Diabetes; Chronic Kidney Disease
Sites: La Jolla, California; Lancaster, California; Lincoln, California · 125 sites in all
- A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or BothPivotal-lookingNot yet recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07931599 · 1,060 participants (planned) · Start Nov 10, 2026 · Primary completion Jul 24, 2028
Drug: Zenagamtide; Semaglutide and 2 more · For: Diabetes Mellitus, Type 2
Sites: La Jolla, California; Lancaster, California; Lincoln, California · 152 sites in all
- A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 DiabetesPivotal-lookingNot yet recruiting
AstraZenecaAstraZeneca (AZN)
NCT07922330 · 330 participants (planned) · Start Jan 4, 2027 · Primary completion Sep 15, 2028
Drug: AZD6234; Placebo · For: Obesity; Overweight; Type 2 Diabetes Mellitus
Sites: Beijing, China; Bozhou, China; Cangzhou, China · 34 sites in all
- A Phase II/III Clinical Study of SIM0811 in the Treatment of Acute Ischemic StrokePivotal-lookingNot yet recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.Industry
NCT07903701 · 1,092 participants (planned) · Start Nov 30, 2026 · Primary completion Jun 30, 2029
Drug: SIM0811 Dose Level A (Phase II); SIM0811 Dose Level B (Phase II) and 4 more · For: Acute Ischemic Stroke AIS
- Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 DiabetesPivotal-lookingNot yet recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07920939 · 450 participants (planned) · Start Nov 2026 · Primary completion Oct 2027
Drug: SHR-3167 Injection; Insulin glargine (IGlar) · For: Type 2 Diabetes
Sites: Nanjing, China; Shanghai, China
- A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and ObesityPivotal-lookingNot yet recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07919405 · 1,408 participants (planned) · Start Nov 11, 2026 · Primary completion Jun 1, 2028
Drug: CagriSema; Semaglutide and 2 more · For: Hypertension; Obesity
Sites: Concord, California; Costa Mesa, California; Fullerton, California · 212 sites in all
- UBT251 Injection Phase Ⅲ Study (OSA-NPAP)Pivotal-lookingNot yet recruiting
The United Bio-Technology (Hengqin) Co., Ltd.Industry
NCT07767942 · 150 participants (planned) · Start Dec 1, 2026 · Primary completion Sep 2028
Drug: UBT251; UBT251 and 1 more · For: Obstructive Sleep Apnea, Obesity
- A Study Comparing SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently Treated With Basal InsulinPivotal-lookingNot yet recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07913061 · 680 participants (planned) · Start Nov 2026 · Primary completion Jan 2028
Drug: SHR-3167; insulin degludec · For: Diabetes Mellitus, Type 2
Sites: Shenzhen, China; Shanghai, China
- Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without DiabetesPivotal-lookingNot yet recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07896265 · 3,000 participants (planned) · Start Nov 18, 2026 · Primary completion Dec 19, 2028
Drug: Olatorepatide; Placebo · For: Overweight or Obesity Without Diabetes
- A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult ParticipantsPivotal-lookingNot yet recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07876492 · 6,106 participants (planned) · Start Nov 20, 2026 · Primary completion Dec 15, 2029
Drug: Cenvacibart; Placebo · For: Secondary Stroke
- A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health ProblemsPivotal-lookingNot yet recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07790861 · 192 participants (planned) · Start Dec 2026 · Primary completion Mar 2028
Drug: Orforglipron; Placebo · For: Obesity; Overweight
Sites: Chengdu, China; Guangzhou, China; Hangzhou, China · 13 sites in all
- A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or ObesityPivotal-lookingNot yet recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07861100 · 8,500 participants (planned) · Start Oct 26, 2026 · Primary completion Sep 16, 2030
Drug: Zenagamtide; Placebo · For: Cardiovascular Risk; Obesity
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 769 sites in all
- Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02)Pivotal-lookingNot yet recruiting
Ollin Biosciences, Inc.Industry
NCT07841899 · 450 participants (planned) · Start Oct 15, 2026 · Primary completion Dec 15, 2028
Drug: OLN324; Aflibercept · For: Diabetic Macular Edema (DME)
- Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-03)Pivotal-lookingNot yet recruiting
Ollin Biosciences, Inc.Industry
NCT07842016 · 450 participants (planned) · Start Oct 15, 2026 · Primary completion Dec 15, 2028
Drug: OLN324; Aflibercept · For: Diabetic Macular Edema (DME)
- A Study of Ecnoglutide Injection in Overweight or Obese Chinese AdolescentsPivotal-lookingNot yet recruiting
Hangzhou Sciwind Biosciences Co., Ltd.Industry
NCT07836270 · 192 participants (planned) · Start Oct 31, 2026 · Primary completion Jun 8, 2028
Drug: Ecnoglutide Injection; placebo with matching volume · For: Adolescents With Obesity; Adolescents With Overweight & Weight-related Comorbidities
Sites: Hangzhou, China
- A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination TherapyPivotal-lookingNot yet recruiting
Addpharma Inc.Industry
NCT07816198 · 354 participants (planned) · Start Sep 30, 2026 · Primary completion Jun 30, 2028
Drug: AD-233A; AD-233B and 4 more · For: Type 2 Diabetes Mellitus (T2DM)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.